Colorectal cancer screening: Stool DNA and other noninvasive modalities

Gut and Liver

Volumn 10, Issue 2, 2016, Pages 204-211

  Bailey, James R ^a   Aggarwal, Ashish ^a,b   Imperiale, Thomas F ^a,b,c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c REGENSTRIEF INSTITUTE   (United States)

Author keywords

Colorectal cancer; Colorectal cancer screening; SDNA; Stool DNA

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; CALGRANULIN; DNA; GLOBIN SPECIFIC ANTIBODY; GUAIAC; HEMOGLOBIN; M2 PYRUVATE KINASE; MICRORNA; OSTEOGENIN; PROTEIN; UNCLASSIFIED DRUG; VIMENTIN; TUMOR MARKER;

CANCER SCREENING; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; FECAL IMMUNOCHEMICAL TEST; FECES; GENE; GENE MUTATION; GENETIC ANALYSIS; GUAIAC BASED FECAL OCCULT BLOOD TEST; HUMAN; IMMUNOCHEMISTRY; NDRG4 GENE; NON INVASIVE PROCEDURE; OCCULT BLOOD; ONCOGENE K RAS; PLASMA; PRECANCER; REVIEW; SENSITIVITY AND SPECIFICITY; TFPI2 GENE; UNITED STATES; COLORECTAL NEOPLASMS; EARLY CANCER DIAGNOSIS; GENETICS; MASS SCREENING; PROCEDURES;

BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; DNA; EARLY DETECTION OF CANCER; FECES; HUMANS; MASS SCREENING;

EID: 84960473794     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl15420     Document Type: Review

References (84)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
3. Edwards BK, Noone AM, Mariotto AB, et al. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 2014;120:1290-1314.
4. Lockhart-Mummery JP, Dukes C. The precancerous changes in the rectum and colon. Surg Gynecol Obstet 1928;36:591-596.
5. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767.
6. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993;329:1977-1981.
7. Brenner H, Chang-Claude J, Seiler CM, Rickert A, Hoffmeister M. Protection from colorectal cancer after colonoscopy: A populationbased, case-control study. Ann Intern Med 2011;154:22-30.
8. DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014;64:252-271.
9. Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: A global overview of existing programmes. Gut 2015; 64:1637-1649.
10. Centers for Disease Control and Prevention (CDC). Vital signs: colorectal cancer screening test use: United States, 2012. MMWR Morb Mortal Wkly Rep 2013;62:881-888.
11. Gupta S, Sussman DA, Doubeni CA, et al. Challenges and possible solutions to colorectal cancer screening for the underserved. J Natl Cancer Inst 2014;106:dju032.
12. Rex DK, Johnson DA, Anderson JC, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol 2009;104:739-750.
13. Burt RW, Cannon JA, David DS, et al. Colorectal cancer screening. J Natl Compr Canc Netw 2013;11:1538-1575.
14. U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008;149:627-637.
15. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: A joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008;134:1570-1595.
16. DeBourcy AC, Lichtenberger S, Felton S, Butterfield KT, Ahnen DJ, Denberg TD. Community-based preferences for stool cards versus colonoscopy in colorectal cancer screening. J Gen Intern Med 2008;23:169-174.
17. Shokar NK, Carlson CA, Weller SC. Informed decision making changes test preferences for colorectal cancer screening in a diverse population. Ann Fam Med 2010;8:141-150.
18. Inadomi JM, Vijan S, Janz NK, et al. Adherence to colorectal cancer screening: A randomized clinical trial of competing strategies. Arch Intern Med 2012;172:575-582.
19. Zapka J, Klabunde CN, Taplin S, Yuan G, Ransohoff D, Kobrin S. Screening colonoscopy in the US: attitudes and practices of primary care physicians. J Gen Intern Med 2012;27:1150-1158.
20. Denberg TD, Melhado TV, Coombes JM, et al. Predictors of nonadherence to screening colonoscopy. J Gen Intern Med 2005;20:989-995.
21. Day LW, Kwon A, Inadomi JM, Walter LC, Somsouk M. Adverse events in older patients undergoing colonoscopy: A systematic review and meta-analysis. Gastrointest Endosc 2011;74:885-896.
22. U.S. Preventive Services Task Force. Guide to clinical preventive services: report of the U.S. Preventive Services Task Force. 2nd ed. Baltimore: Williams & Wilkins, 1996.
23. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993;328:1365-1371.
24. Libby G, Brewster DH, McClements PL, et al. The impact of population-based faecal occult blood test screening on colorectal cancer mortality: A matched cohort study. Br J Cancer 2012;107:255-259.
25. Scholefield JH, Moss SM, Mangham CM, Whynes DK, Hardcastle JD. Nottingham trial of faecal occult blood testing for colorectal cancer: A 20-year follow-up. Gut 2012;61:1036-1040.
26. Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer. N Engl J Med 2013;369:1106-1114.
27. Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996;334:155-159.
28. Church TR, Ederer F, Mandel JS. Fecal occult blood screening in the Minnesota study: sensitivity of the screening test. J Natl Cancer Inst 1997;89:1440-1448.
29. Lang CA, Ransohoff DF. Fecal occult blood screening for colorectal cancer: is mortality reduced by chance selection for screening colonoscopy? JAMA 1994;271:1011-1013.
30. Ederer F, Church TR, Mandel JS. Fecal occult blood screening in the Minnesota study: role of chance detection of lesions. J Natl Cancer Inst 1997;89:1423-1428.
31. Allison JE, Fraser CG, Halloran SP, Young GP. Population screening for colorectal cancer means getting FIT: The past, present, and future of colorectal cancer screening using the fecal immunochemical test for hemoglobin (FIT). Gut Liver 2014;8:117-130.
32. Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med 2014;160:171.
33. Chiu HM, Lee YC, Tu CH, et al. Association between early stage colon neoplasms and false-negative results from the fecal immunochemical test. Clin Gastroenterol Hepatol 2013;11:832-838.e2.
34. de Wijkerslooth TR, Stoop EM, Bossuyt PM, et al. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia. Am J Gastroenterol 2012;107:1570-1578.
35. Quintero E, Castells A, Bujanda L, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 2012;366:697-706.
36. VA Office of Research and Development. Colonoscopy versus fecal immunochemical test in reducing mortality from colorectal cancer (CONFIRM). 2010 Nov 9 [last updated 2015 Jul 23; cited 2015 Jul 30]. In: ClinicalTrials.gov [Internet]. Bethesda: U.S. National Library of Medicine; 2000-. Available from: https://clinicaltrials. gov/ct2/show/NCT01239082.
37. Guittet L, Bouvier V, Mariotte N, et al. Comparison of a guaiac and an immunochemical faecal occult blood test for the detection of colonic lesions according to lesion type and location. Br J Cancer 2009;100:1230-1235.
38. Cole SR, Young GP. Effect of dietary restriction on participation in faecal occult blood test screening for colorectal cancer. Med J Aust 2001;175:195-198.
39. Cole SR, Young GP, Esterman A, Cadd B, Morcom J. A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer. J Med Screen 2003;10:117-122.
40. van Rossum LG, van Rijn AF, van Oijen MG, et al. False negative fecal occult blood tests due to delayed sample return in colorectal cancer screening. Int J Cancer 2009;125:746-750.
41. Wong CK, Fedorak RN, Prosser CI, Stewart ME, van Zanten SV, Sadowski DC. The sensitivity and specificity of guaiac and immunochemical fecal occult blood tests for the detection of advanced colonic adenomas and cancer. Int J Colorectal Dis 2012;27:1657-1664.
42. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993;9:138-141.
43. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-170.
44. Ahlquist DA, Harrington JJ, Burgart LJ, Roche PC. Morphometric analysis of the "mucocellular layer" overlying colorectal cancer and normal mucosa: relevance to exfoliation and stool screening. Hum Pathol 2000;31:51-57.
45. Ahlquist DA, Skoletsky JE, Boynton KA, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000;119:1219-1227.
46. Dong SM, Traverso G, Johnson C, et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 2001;93:858-865.
47. Syngal S, Stoffel E, Chung D, et al. Detection of stool DNA mutations before and after treatment of colorectal neoplasia. Cancer 2006;106:277-283.
48. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME; Colorectal Cancer Study Group. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004;351:2704-2714.
49. Ahlquist DA, Sargent DJ, Loprinzi CL, et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med 2008;149:441-450.
50. Zou H, Harrington JJ, Klatt KK, Ahlquist DA. A sensitive method to quantify human long DNA in stool: relevance to colorectal cancer screening. Cancer Epidemiol Biomarkers Prev 2006;15:1115-1119.
51. Itzkowitz S, Brand R, Jandorf L, et al. A simplified, noninvasive stool DNA test for colorectal cancer detection. Am J Gastroenterol 2008;103:2862-2870.
52. Ahlquist DA, Zou H, Domanico M, et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology 2012;142:248-256.
53. Lidgard GP, Domanico MJ, Bruinsma JJ, et al. Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia. Clin Gastroenterol Hepatol 2013;11:1313-1318.
54. Diehl F, Schmidt K, Durkee KH, et al. Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology 2008;135:489-498.
55. Zou H, Taylor WR, Harrington JJ, et al. High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. Gastroenterology 2009;136:459-470.
56. Zou H, Allawi H, Cao X, et al. Quantification of methylated markers with a multiplex methylation-specific technology. Clin Chem 2012;58:375-383.
57. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014; 370:1287-1297.
58. Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, Wilschut JA, Zauber AG, van Ballegooijen M. Stool DNA testing to screen for colorectal cancer in the Medicare population: A cost-effectiveness analysis. Ann Intern Med 2010;153:368-377.
59. Skally M, Hanly P, Sharp L. Cost effectiveness of fecal DNA screening for colorectal cancer: A systematic review and quality appraisal of the literature. Appl Health Econ Health Policy 2013; 11:181-192.
60. Patel SS, Kilgore ML. Cost effectiveness of colorectal cancer screening strategies. Cancer Control 2015;22:248-258.
61. Exact Sciences. Exact Sciences provides update on strong launch trajectory of Cologuard [Internet]. Madison: Exact Sciences; 2015 [cited 2015 Jun 25]. Available from: http://www.exactsciences. com/about/latest-news/update-on-strong-launch-trajectory-ofcologuard
62. Yang W, Lee DY, Ben-David Y. The roles of microRNAs in tumorigenesis and angiogenesis. Int J Physiol Pathophysiol Pharmacol 2011;3:140-155.
63. Koga Y, Yasunaga M, Takahashi A, et al. MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer Prev Res (Phila) 2010;3:1435-1442.
64. Wu CW, Ng SS, Dong YJ, et al. Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut 2012;61:739-745.
65. Ng EK, Chong WW, Jin H, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: A potential marker for colorectal cancer screening. Gut 2009;58:1375-1381.
66. Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 2014;63:317-325.
67. Ahlquist DA, Taylor WR, Mahoney DW, et al. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. Clin Gastroenterol Hepatol 2012;10:272-277. e1.
68. Jin P, Kang Q, Wang X, et al. Performance of a second-generation methylated SEPT9 test in detecting colorectal neoplasm. J Gastroenterol Hepatol 2015;30:830-833.
69. Dickinson BT, Kisiel J, Ahlquist DA, Grady WM. Molecular markers for colorectal cancer screening. Gut 2015;64:1485-1494.
70. Hoff G, Grotmol T, Thiis-Evensen E, Bretthauer M, Gondal G, Vatn MH. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT). Gut 2004;53:1329-1333.
71. Shastri YM, Loitsch S, Hoepffner N, et al. Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study. Am J Gastroenterol 2008;103:1496-1504.
72. Tonus C, Sellinger M, Koss K, Neupert G. Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: A meta-analysis. World J Gastroenterol 2012;18:4004-4011.
73. Haug U, Rothenbacher D, Wente MN, Seiler CM, Stegmaier C, Brenner H. Tumour M2-PK as a stool marker for colorectal cancer: comparative analysis in a large sample of unselected older adults vs colorectal cancer patients. Br J Cancer 2007;96:1329-1334.
74. Naumann M, Schaum B, Oremek GM, et al. Faecal pyruvate kinase type M2: A valid screening parameter for colorectal cancer? Preliminary results from a multicenter comparative study. Dtsch Med Wochenschr 2004;129(34-35):1806-1807.
75. Uppara M, Adaba F, Askari A, et al. A systematic review and meta-analysis of the diagnostic accuracy of pyruvate kinase M2 isoenzymatic assay in diagnosing colorectal cancer. World J Surg Oncol 2015;13:48.
76. Centers for Medicare & Medicaid Services. Clinical laboratory fee schedule 2015 [Internet]. Baltimore: Centers for Medicare & Medicaid Services; 2015 [cited 2015 Jul 30]. Available from: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/clinlab.html.
77. Ahlquist DA. Multi-target stool DNA test: A new high bar for noninvasive screening. Dig Dis Sci 2015;60:623-633.
78. Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 2014;63:317-325.
79. Barton A. Blood test for colon cancer removes the 'ick' factor [Internet]. Vancouver: The Globe and Mail; 2010 [cited 2015 Jul 30]. Available from: http://www.theglobeandmail.com/life/healthand-fitness/blood-test-for-colon-cancer-removes-The-ick-factor/article572600/.
80. StatLabs [Internet]. StatLabs; 2015 [cited 2015 Jul 30]. Available from: http://www.estatlabs.com/products/ColoVantage-%28methylated-Septin-9-biomarker-for-colon-cancer-screening% 29.html.81.
81. Greegor DH. Diagnosis of large-bowel cancer in the asymptomatic patient. JAMA 1967;201:943-945.
82. Hill MJ, Morson BC, Bussey HJ. Aetiology of adenoma: carcinoma sequence in large bowel. Lancet 1978;1:245-247.
83. Barrows GH, Burton RM, Jarrett DD, Russell GG, Alford MD, Songster CL. Immunochemical detection of human blood in feces. Am J Clin Pathol 1978;69:342-346.
84. Centers for Medicare & Medicaid Services. Decision memo for screening immunoassay fecal-occult blood test (CAG-00180N) [Internet]. Baltimore: Centers for Medicare & Medicaid Services; 2003 [cited 2015 Jul 30]. Available from: https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NC AId=87&TAId=20&IsPopup=y&bc=AAAAAAAAAgAAAA%3D% 3D&.